Clinical trials: Stage I Prostate Cancer
Cancer Of Prostate, Prostate Neoplasms
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Background: Sometimes prostate cancer comes back after a person's prostate is removed. In this case, radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective.
- Conditions
- Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate
- Trial name
- NCT03388619
- Testing
- Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03274687
- Testing
- Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 241 sites in United States, Canada and 1 more
- Volunteers
- 296 people
- Sponsor
- NRG Oncology
Prostate Cancer
A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer
Subjects will be asked to participate in this clinical trial to examine the safety of 2-deoxyglucose (an agent which is quite similar to glucose) in the treatment of solid tumors and hormone refractory prostate cancer.
- Trial name
- 2-Deoxyglucose (NCT00633087)
- Testing
- 2-deoxyglucose
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rutgers, The State University of New Jersey
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Genistein in Treating Patients With Prostate Cancer
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT01126879
- Testing
- genistein, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Prostatic Neoplasms
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Background: Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate tumors respond to it.
- Trial name
- NCT01683994
- Testing
- Cabozantinib, Docetaxel, Prednisone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of alisertib when given together with abiraterone acetate and prednisone and to see how well it works in treating patients with hormone-resistant prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01848067
- Testing
- Alisertib, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery.
- Conditions
- Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT02830165
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonsson Comprehensive Cancer Center
PSA Level Less Than or Equal to Fifteen, PSA Level Less Than Ten
Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in patients with prostate cancer that is limited to a certain part of the body (localized), who have chosen observation as their treatment…
- Conditions
- PSA Level Less Than or Equal to Fifteen, PSA Level Less Than Ten, Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7
- Trial name
- NCT02095145
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Pomegranate-Extract Pill
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Conditions
- Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
- Trial name
- NCT01434290
- Testing
- 36.25 Gy IMRT, 51.6 Gy IMRT
- Where
- 37 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Neoplasms
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
- Trial name
- NCT00473746
- Testing
- Abiraterone acetate, prednisone/prednisolone or dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 66 people
- Sponsor
- Janssen Research & Development, LLC
Lung Cancer, Tobacco Use Disorder
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population.
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer
- Trial name
- NCT01434342
- Testing
- Nicotine Replacement Patch
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Wake Forest University Health Sciences
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with cyclophosphamide and to see how well they work in treating patients with previously treated hormone-refractory prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01093183
- Testing
- lenalidomide, cyclophosphamide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Nebraska
Prostate Cancer
Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: The use of lycopene, a substance found in tomatoes, or omega-3 fatty acid nutritional supplements may keep cancer from growing in patients with prostate cancer.
- Trial name
- NCT00402285
- Testing
- lycopene supplement, fish oil supplement
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of California, San Francisco
Hot Flashes, Prostate Cancer
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
RATIONALE: Soy protein/isoflavones and venlafaxine may help relieve hot flashes in patients receiving hormone therapy for prostate cancer.
- Trial name
- NCT00354432
- Testing
- oral soy protein/isoflavones powder, Venlafaxine
- Where
- 20 sites in United States
- Volunteers
- 120 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer, Prostatic Neoplasm
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Background: Prostate cancer is the second leading cause of cancer death in United States (U.S.) men. Radiation is an effective treatment for most patients with localized prostate cancer, but sometimes the tumor returns.
- Trial name
- NCT03253744
- Testing
- 18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
The purpose of this research study is to determine the safety of giving ketoconazole, hydrocortisone and dutasteride (KHAD) with lapatinib.
- Trial name
- KHLAD (NCT00953576)
- Testing
- ketoconazole, hydrocortisone, dutasteride
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Stage I Prostate Cancer, Stage IIA Prostate Cancer
Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
This randomized phase II trial studies how well green tea extract works in treating patients with low-risk prostate cancer. Green tea extract contains ingredients that may prevent or slow the growth of certain cancers.
- Conditions
- Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT01928485
- Testing
- active surveillance, Sunphenon, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sanjay Gupta PhD
Prostate Cancer
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
The purpose of this study is to find the highest dose level of the study drug, 177Lu-PSMA-617 that can be given without severe side effects for advanced prostate cancer.
- Trial name
- NCT03042468
- Testing
- 177Lu-PSMA-617, 68Ga-PSMA-HBED-CC
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
RATIONALE: Green tea contains ingredients that may prevent or slow the growth of certain cancers. It is not yet known whether green tea is more effective than black tea or water in treating prostate cancer.
- Trial name
- NCT00685516
- Testing
- green tea, decaffeinated black tea
- Where
- 2 sites in United States
- Volunteers
- 113 people
- Sponsor
- Jonsson Comprehensive Cancer Center